Lab
Biogene Diagnostics INC.
Biogene Diagnostics INC. was paid $51K by Medicaid between Dec 2023 and Dec 2024, across 24 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 72% of everything it billed.
33Billing provider infoBIOGENE DIAGNOSTICS INC.
LOS ALAMITOS, CA 90720
LOS ALAMITOS, CA 90720
33aNPI1093490112assigned 06/16/2023
33bProvider typeClinical Medical Laboratory
28Total paid$51K
24GClaims3,424
24DCodes billed24
24AFirst – last monthDec 2023 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#362 of 561
Median peer was paid$222K
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 80 | $2K | |
| 2024incomplete | 3,344 | $50K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 72% | 2,029 | 894 | $37K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 21% | 204 | 194 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 309 | 291 | $679.88 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 60 | 58 | $511.38 |
| 80053 | Comprehensive metabolic panel | <1% | 131 | 126 | $447.12 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 96 | 90 | $447.05 |
| 80061 | Lipid panel | <1% | 75 | 73 | $338.60 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 60 | 58 | $323.16 |
| 86481 | <1% | 16 | 16 | $282.60 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 60 | 58 | $145.47 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 42 | 42 | $124.16 |
| 87634 | <1% | 42 | 42 | $101.08 |
12 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialABULATHOA, ZEYAD (PRESIDENT)